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Abstract
Background: Anticoagulation therapy is used for atrial fibrillation (AF) patients for reducing the risk of
cardioembolic complications such as stroke. The previously recommended anticoagulant, warfarin, has a narrow
therapeutic window, and it requires regular laboratory monitoring, unlike direct oral anticoagulants (DOAC). From a
societal perspective, it is important to measure time and travel costs associated with warfarin monitoring to better
compare the total therapy costs of these two alternative forms of anticoagulation management. In this study we
design a georeferenced cost model to investigate societal savings achievable with the shift from warfarin to DOACs
in the study region of North Karelia in Eastern Finland.
Methods: Individual-level patient data of 6519 AF patients was obtained from the regional patient database.
Patients’ geocoded home addresses and other GIS data were used to perform a network analysis for the optimal
routes for warfarin monitoring visits. These measures of revealed accessibility were then used in the cost model to
measure monetary time and travel costs in addition to direct healthcare costs of anticoagulation management.
Results: The share of time and travel costs in warfarin monitoring is 26.6% of the total therapy costs in our study
region. With current drug retail prices in Finland, the societal expense of anticoagulation management is only 2.6%
higher with DOACs than in the baseline with warfarin. However, when 25% lower distributor’s prices are used, the
total societal cost decreases by 13.6% with DOACs.
Conclusions: Our results indicate that patients’ time and travel costs critically increase the societal cost of warfarin
therapy; and despite the higher price of DOACs, they are already cost-efficient alternatives to warfarin in
anticoagulation management. In the future, the cost of AF complications should be included in the cost
comparison between warfarin and DOACs. Our modeling approach applies to different geographical regions and to
different healthcare processes requiring patient monitoring.
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Background
Atrial fibrillation (AF), which is associated with in-
creased risk of ischemic stroke (IS), systemic embolism,
heart failure, and mortality [1], is the most common
arrhythmic condition in developed countries. With in-
creasing prevalence, especially among population over
65 years old, it has become a significant public health
problem and a cause of increasing healthcare expend-
iture. Previously, warfarin has been the primary recom-
mended anticoagulant for reducing the risk of IS. But
the current recommendation given by the European
Society of Cardiology also emphasizes the benefits of
direct oral anticoagulants (DOACs) [2].
As warfarin has a narrow therapeutic range, a safe
use of it requires regular monitoring of the anticoagu-
lation effect through blood tests. The international
normalized ratio (INR) target range measured by a
blood test is set between 2 and 3 [3]. Underanticoagu-
lation may lead to thrombotic events, and overanticoa-
gulation has the risk of hemorrhage [3, 4]. Yet the
monitoring can be a significant burden for patients as
it involves a number of clinic or laboratory visits
dependent on the achieved INR level [5]. Compared
with warfarin, direct oral anticoagulants (DOAC) seem
to have some therapeutic benefits such as the reduc-
tion of hemorrhagic strokes and systemic embolic
events [6], and patients with DOACs do not require
regular laboratory monitoring. On the other hand, the
higher price of DOACs has maybe thus far been redu-
cing their use in anticoagulation management.
The cost-effectiveness of DOACs has been assessed
in multiple studies [7–9]. Respectively, patients’ travel
costs associated with the warfarin therapy have been
addressed in a few studies [10–13] . However, to our
knowledge, only one study has considered time and
travel costs when comparing the total costs of anticoa-
gulation management for warfarin and DOACs. Mar-
colino et al. [14] report that in the Brazilian context,
the cumulative costs per patient using warfarin with
follow-up in anticoagulation clinics is currently higher
than the strategy of using DOACs. This outcome is not
surprising, but this topic could also be studied further,
as the patient data for the study of Marcolino et al.
[14] was collected from a single anticoagulation clinic
using a time period of just 3 months.
The opportunity costs of medical choices require fur-
ther investigation also in the geographical context, as the
shift from warfarin to DOACs would eliminate the bur-
den of INR monitoring and create societal savings when
time and travel costs are considered. Additionally, the
increment of DOAC therapy would mitigate the import-
ance of access to healthcare in anticoagulation manage-
ment especially in sparsely populated rural areas where
the health services are harder and more expensive to
reach due to longer distances. For regularly monitored
medical conditions, travel time and distance can even
create barriers to effective use of services [15, 16].
Traveling needed to reach health services incurs
costs to both patients and society; but all additional
costs, including travel costs and the value of lost leis-
ure time and production loss, are often ignored in eco-
nomic evaluations, which tend to focus on the direct
monetary costs of care [10, 11]. Nevertheless, it has
been shown that patient time and travel costs associ-
ated with receiving healthcare services may be critical,
and they should be included in the economic assess-
ments of interventions that require regular monitoring
and traveling [10, 17–19]. Considering the total cost of an
intervention, patient time and travel costs have been re-
ported to be 21% in type 2 diabetes follow-up in Finland
[17] and 20–40% in cancer screening in the UK [18].
Aim of the study
With the higher price of DOAC drugs but minuscule
monitoring costs compared with warfarin, it is important
to measure and compare the total costs of these two al-
ternative anticoagulation managements. Thus far, the
previous cost comparisons including time and travel
costs have not covered larger geographical areas or used
electronic health records (EHRs). Hence, the aim of our
study was to use patient register data to measure re-
vealed healthcare accessibility as monetary cost, and to
investigate the potential savings of travel and time costs
achievable with the shift from warfarin to DOACs. We
evaluated whether these simulated savings are enough to
create societal savings in the total costs of anticoagula-
tion management in a regional public healthcare setting
in North Karelia Eastern Finland.
Methods
Study region and patient data
The study area in Eastern Finland includes the region
of North Karelia and the nearby municipality of Heinä-
vesi, which belongs to the same healthcare district of
Siun sote (14 municipalities, 166,000 inhabitants, a
population density of 8.8 per km2 (22.9 per mi2), degree of
urbanization 76.2%). The population is distributed un-
evenly among more densely populated centers and
sparsely populated rural areas. Specialized healthcare ser-
vices can be acquired from the central hospital and pri-
mary care services from 23 public healthcare centers.
The unique characteristic in the region in Finland is
the common electronic patient database used by all mu-
nicipalities. This regional patient database (Mediatri)
holds all public healthcare records from the healthcare
district. For this study, all AF (ICD-10 code I48) patients
(N = 6519) having the diagnosis day between 1.1.1996
and 12.31.2016 were included in the study with the
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conditions that they were alive at the end of 2017, they
had at least one healthcare visit with an AF diagnosis
between 2014 and 2017, and their home address could
be geocoded. The measurement timeline for this patient
sample was the year 2017, for which the data retrieval
from Mediatri consisted of individual-level patient data,
such as gender, age, domicile, diagnoses, laboratory re-
sults, prescriptions and healthcare center visits.
As we were interested in the medication use in 2017,
we identified patients who had recently switched from
warfarin to a DOAC medication and assumed that
DOAC prescription, even overlapping with warfarin pre-
scription, at the end of the year 2017 indicated that the
patient had switched to DOAC during the year. These
patients were counted as DOAC users in addition to pa-
tients who had been using DOAC for more than a year.
The rest of the patients with warfarin prescription but
without DOAC prescription were treated as warfarin
users, if they had at least 1 INR measurement in 2017.
This additional criterion helped to confirm the warfarin
use, as our data lacked the information whether the pa-
tients have redeemed their warfarin prescriptions. How-
ever, following this decision all patients who might have
be using warfarin without going to INR monitoring were
excluded from the group of warfarin users.
In Finland, INR is routinely measured at sample col-
lection points at local clinics (called an INR sampling
point in this study). The results from both normal la-
boratory measurements and from INR quick tests per-
formed by nurses are registered in the same database.
After a laboratory measurement, the patient receives in-
structions for warfarin dosage adjustment by an SMS
message or in some cases, by a phone call. For warfarin
users in North Karelia, the average distance to the clos-
est INR sampling point along a road network is 6.2 km.
We checked the number of patients using self-
monitoring devices in the region, but due to the low
number of users (N = 23), self-monitoring was eventually
not considered in the study setting.
The cost model
We measured both the patients’ costs of travel and time
loss and direct anticoagulation management costs using
a georeferenced cost model, which is an application of
the previous model for the travel and time costs of type
2 diabetes by Leminen et al. [17]. The model was devel-
oped further in order to measure the societal costs of
anticoagulation management performed with either war-
farin or DOACs. The model consists of patient travel
costs with four different travel modes based on a net-
work analysis, the monetary value of patient time loss
associated with traveling and INR measurements, and
direct anticoagulation management costs (such as the
cost of INR blood tests and the medication costs of war-
farin or DOACs).
These costs can be expressed with equations for every
travel mode, similarly to the previous studies of Ford
et al. [20] and Leminen et al. [17]. Walking (CWALK), pri-
vate car (CCAR), bus (CBUS) and taxi (CTAXI) are
expressed with the following equations:
CWALK ¼ TVOTP ð1aÞ
CCAR ¼ T þ Tp
 VOTP þ DVOC ð1bÞ
CBUS ¼ T þ Tað ÞVOTP þ F ð1cÞ
CTAXI ¼ T þ Tað ÞVOTP þ F þ DVOC ð1dÞ
where T is the travel time, VOT (value of time) is the
gross wage coefficient of the patient’s zip code area, P is
the patient’s productivity coefficient (used as weight for
VOT to depict patient’s lost contribution to the society
based on lost working time and leisure), Tp is the vehicle
parking time, D is the road distance in km, VOC is the
vehicle operating cost per km, Ta is the access time to
the network (walking time to a bus stop or from a bus
stop to the clinic or laboratory, waiting time at the bus
stop, or service time in a taxi), and F is the bus fare or
the fixed charge of taxi paid for the journey. Anticoagu-
lation management related costs are calculated differ-
ently for warfarin therapy (CWARF) and DOAC therapy
(CDOAC):
CWARF ¼ TinrVOTP þ Cinr þ Ct þ Cm ð2aÞ
CDOAC ¼ Cm ð2bÞ
where Tinr is the time spent in the INR monitoring visit
and adjusting the warfarin dosage according to counsel-
ling via SMS, VOT (value of time) is the gross wage
coefficient of the patient’s zip code area, P is the pa-
tient’s productivity coefficient (used as weight for VOT
to depict patient’s lost contribution to the society based
on lost working time and leisure), Cinr is the cost of the
INR monitoring visit, Ct is the cost of the INR blood test
(sampling and blood test), and Cm is the cost of medica-
tion (warfarin or DOACs).
The cost model was executed following the flow chart
presented in Fig. 1. At baseline, the costs were calculated
based on the medication data from 2017. Next, we de-
signed a scenario where warfarin was replaced with
DOACs for patients who had no contraindications for
the drug. Thus, because of safety concerns or lack of suf-
ficient evidence, patients with a prosthetic heart valve or
chronic kidney disease (N = 296) were determined to
continue using warfarin.
Additionally, warfarin users with less than 5 annual
INR measurements (N = 553) were excluded from the
new DOAC users, as we had evidence of a measurement
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registration problem in the area of 3 municipalities.
These excluded patients had stayed long periods in nurs-
ing homes and wards, and despite close monitoring,
most of them had only few registered INR measure-
ments in 2017. Additional measurements made by
nurses were not registered in the patient database due to
the differences in medical practice. Thus, based on the
registered data, these patients did not represent regularly
monitored patients and the switch to DOAC would have
increased costs unrealistically for them. It should be
noted, though, that this leaves the possibility of a small
number of patients being excluded, even though their
low number of INR measurements might be correct, and
they just did not go for their appointed measurements.
Travel modes
When measuring travel time and travel costs, the choice
of travel mode is the first thing to identify. The
Fig. 1 Flow chart of the cost model
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determination of each patient’s travel mode can be a
challenge, as the travel mode choice is influenced by
multiple factors such as age, gender, income, education,
employment, family size, number of children, and car
ownership [21–23]. Thus, with limited data and without
time-consuming inquiries, some generalizations are ne-
cessary. A high age associated with diseases like atrial
fibrillation changes patients’ travel patterns, especially if
they are entitled to travel cost reimbursements, like in
Finland. Travel expenditures are usually compensated
for according to the least expensive travel mode, but
more expensive taxi trips are accepted for health reasons
or when suitable public transport is not available.
Four travel modes—private car, taxi, walking and
bus—for patients using warfarin were selected following
the criteria in Table 1. These criteria are based on the
classifications made in the previous study by Leminen
et al. [17] in the same study area. From a total of 4560
patients using warfarin, 3961 were included in the travel
cost analysis. Additional 599 warfarin users in sheltered
homes were excluded, but the cost of annual INR mea-
surements was still calculated for this patient group.
GIS based network analysis
From a patient’s perspective, the effort and cost to
reach an anticoagulation clinic or laboratory are
dependent on the accessibility of the services used.
The geographical accessibility and availability of ser-
vices, commonly called spatial accessibility [24–26], is
affected by the locations of destinations (supply) and
starting points (demand) as well as the performance of
the transportation system [27].
Accessibility to healthcare services is usually measured
by distance, travel time, or monetary costs; and for large
areas, this can be done most easily with GIS (geographic
information system) methods using either vector- or
raster-based analysis [28]. The use of vector-based
network analysis has increased along with the better
availability of transport network high-quality data [29].
New measures such as the shortest and fastest routes
based on the road network also yield more accurate re-
sults compared with a simple straight-line distance [30].
The measured accessibility can be both potential (when
focusing on the hypothetical use of the available health-
care services) and revealed (when measuring the actual
utilization of the resources) [24, 26, 31]. Our study
setting builds on the revealed accessibility, as the trip
frequency is based on patient information and the real
number of INR monitoring visits in 2017.
We conducted the GIS based network analysis using
the Origin-Destination (OD) Cost Matrix method [32] in
Esri ArcGIS Pro 2.2 software (Esri, Redlands, CA, USA).
The used road network data was modified from the
Digiroad database by the Finnish Transport Agency.
Optimal routes between patient home addresses and
INR sampling points were calculated based on travel
time, as previously suggested by Ray & Ebener [28]
and the World Health Organization (WHO) [33]. Add-
itionally, travel distance was saved simultaneously
based on these fastest routes. Because the study area
has no notable traffic congestion and the INR monitor-
ing is premeditated, the rush hour variability of acces-
sibility was not needed in travel times. The calculated
travel time and travel distance for two-way journeys
were later converted as monetary costs in the cost
model (Fig. 1).
Cost values and sensitivity analysis
The cost of travel, the time cost of both travel and ther-
apy, and the clinical cost of INR measurements and
monitoring were calculated using parameters in Table 2
for eqs. (1a)–(2a). The time spent on traveling and INR
monitoring was valued based on the average hourly in-
come derived from the patient’s zip code area income
data of 2017. Additionally, following Jowett et al. [10], a
separate coefficient was used to weigh the productivity
level of working-age (< 63 years) and retired (≥ 63 years)
patients. The time loss for a working-age patient was
considered equal to the average hourly gross wage, and
the leisure time for a pensioner was valued at 35% of the
average wage. All other monetary values, including the
cost of medication, were based on the current prices
(October 1, 2018) in the study area.
Table 1 Characteristics of selected travel modes
Travel mode Number of patients Criteria Travel speed
Private car 2132 Distance to the INR sampling point > 1 km, bus not an option and
patient age < 80 years or distance to the INR sampling point > 0.2 km and
patient age < 85 years
Road speed limit
Taxi 925 Patient age≥ 85 years Road speed limit
Walking 546 Distance to the closest INR sampling point ≤1 km and patient age < 80 years, or
distance ≤0.2 km and patient age < 85 years
4 km/h
Bus 358 Distance to the closest INR sampling point > 1 km, destination accessible by bus,
distance to the closest bus stop ≤0.25 km and patient age < 80 years
30 km/h (average speed
based on timetables)
Total 3961
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For the costs of warfarin and DOAC medications, we
used national retail prices (excluding VAT), as well as
lower drug distributor’s prices, which can be regarded as
the wholesale prices. The retail prices reflected the real
value, which included the statutory profit margin of
Finnish pharmacies. The alternative distributor’s prices
were vital, as our measurement goal was to measure the
social opportunity costs of the two medical choices, and
unlike for warfarin, the price for DOACs was crucial in
this regard. These wholesale prices without any added
value offer useful information for the decision-makers
about the economic viability of the transitioning from
warfarin to DOACs. In the scenario, both prices were
presented as the average price of four different DOACs.
As travel costs depend on the distance and the
number of trips, the sensitivity of the travel costs was
simulated for the artificial travel distance (2 km, 5 km,
10 km, 20 km, and 30 km) and for the artificial num-
ber of annual INR monitoring visits (5, 10, 15, and
20), with the assumption that each trip is made by
private car. Additional sensitivity analysis for the costs
of warfarin therapy included the artificial number of
annual INR measurements (5, 10, 15, and 20) and the
different values for leisure time (20, 35 and 50% of
Table 2 Parameters of the model
Parameter Description Value Unit Additional information
T Travel time using the fastest route on a road
network
min Calculated with network analysis
VOT The value of time based on the average hourly
income of a zip code area
EUR Average hourly gross wage converted from the
monthly gross wage in 2017
P Patient’s productivity coefficient 1.00 or 0.35 Used as
weight
Depicts patient’s lost contribution to the society.
Working time is valued as 100% and leisure time as
35% of the hourly wage
Tp Private car parking time 5 min Added to the total journey time
D Travel distance calculated from the fastest route on
a road network
km Calculated with network analysis
VOC Vehicle operating cost
Private car 0.45 EUR/km Includes fuel cost and vehicle maintenance and
depreciation costs
Taxi 1.60 EUR/km Most common fare per km
Ta Network access time
Taxi service time 5 min Added to the total journey time
Waiting time in a bus stop 7 min Added to the total journey time
Walking time to a bus stop 5 min Added to the total journey time
Walking time from a bus stop to home or clinic 5 min Added to the total journey time
F Fare paid for the journey
One-way bus fare 2.00, 3.80 or
5.00
EUR Fare depends on the fare zone
Taxi initial fixed charge 5.90 EUR Most common fee in the study area
Tinr Patient time loss associated with INR monitoring 40 min Blood test and the adjustment of warfarin dosage
Cinr Cost of the INR monitoring visit 25.00 EUR Includes healthcare personnel costs (result examination,
warfarin dosage counseling via SMS or phone call and
making the next appointment) based on the service
provider prices for nurse/doctor phone consultation
Ct Cost of the INR blood test 10.50 EUR Sampling 7.50 € + test 3.00 €
Cm Cost of the medication
Warfarin 3.90/2.20 EUR/mo. Retail price (excl. VAT)/distributor’s price. Calculated with
the average consumption of 5 mg/day
Apixaban 82.40/59.50 EUR/mo. Retail price (excl. VAT)/distributor’s price
Dabigatran 82.40/59.50 EUR/mo. Retail price (excl. VAT)/distributor’s price
Rivaroxaban 74.00/59.40 EUR/mo. Retail price (excl. VAT)/distributor’s price
Edoxaban 73.80/59.40 EUR/mo. Retail price (excl. VAT)/distributor’s price
All monetary values, except the value of time, are based on the prices (EUR) on October 1, 2018
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the average gross wage per hour) due to the lack of
profound consensus on its valuation. Here we wanted
to test the impact of different values on time costs by
adding two arbitrary values around the value of 35%
suggested earlier by Jowett et al. [10].
Results
Characteristics of the patient group
Approximately 4.0% (N = 6594) of the population liv-
ing in the healthcare district had a diagnosed AF at the
end of 2016. After geocoding the home addresses of
this patient sample with a success rate of 98.9%, the
final number of patients included in the study was
6519. The mean age of these patients was 76.5 years,
and 54.2% were men. Of this patient group, 94.0% had
at least one INR measurement between 2014 and 2017,
and the time in therapeutic range (TTR) for 2017
could be determined for 72.5% of the patients with
warfarin. The detailed characteristics for the geocoded
patient group are shown in Table 3.
When classified by the used medication, 70.0% (N =
4560) of patients had a warfarin prescription and at
least 1 INR measurement in 2017. Respectively, 19.0%
(N = 1239) of the patients had a DOAC prescription
(6.4% apixaban, 6.4% rivaroxaban, 6.1% dabigatran, and
0.1% edobaxan). The share of the patients without
medication was 11.0% (N = 720). Surprisingly, the
usage of warfarin was most common in distant areas,
where the travel distance to an INR sampling point is
long (Fig. 2).
Cost analysis
In our study area, warfarin therapy costs for the patient
group were approximately 3,800,000 EUR / 4,410,000
USD (1 EUR = 1.1606 USD, on October 1, 2018) in 2017
when considering both direct costs and the cost types
regarded as indirect costs (Table 4). Overall, these indir-
ect costs constitute 26.6% of the total annual costs.
The annual travel costs in warfarin therapy in the
study area are 815,090 EUR / 945,990 USD (1 EUR =
1.1606 USD), which is an average of 206 EUR / 239
USD per patient and 14 EUR / 16 USD per journey
(Table 5). Of the travel costs, 87.8% are direct costs
and 12.2% are time costs. In the cost model, private
car and taxi are the most used travel modes, and this is
also displayed in their large share of the total travel
costs. Taxi is the most expensive mode of travel even
in short distances. Thus, pensioners have on average
higher travel costs than working-age patients, as pa-
tients 85 years old and above were expected to use a
taxi. However, because of the lower valuation for leis-
ure time, the travel costs for pensioners are relatively
lower by private car, bus, and walking.
We also performed two sensitivity analyses. First, the
sensitivity of the costs of warfarin therapy was tested
using three different valuations of leisure time and four
numbers of INR monitoring visits. The results in
Table 6 show that the valuation of leisure time has a
minor effect on the total costs of warfarin therapy.
With each number of annual INR measurements, the
share of indirect costs is approximately 2 percentage
points higher when leisure time is valued at 35% of the
Table 3 Characteristics of the patient group
Variable All geocoded patients
(N = 6519)
Warfarin
(N = 4560)
DOACs
(N = 1239)
No medication
(N = 720)
Age, mean (SD) 76.5 (10.5) 78.1 (9.4) 75.1 (10.1) 68.5 (13.5)
Retired, age≥ 63 years, n (%) 5896 (90.5) 4302 (94.3) 1103 (89.0) 491 (68.2)
Gender, male, n (%) 3532 (54.2) 2388 (52.4) 663 (53.5) 481 (66.8)
BMI, mean (SD) 29.1 (6.2) 29.3 (6.4) 29.3 (5.8) 28.1 (5.4)
Obesity (BMI > 30), n (%) 1456 (22.3) 1006 (22.1) 327 (26.4) 123 (17.1)
CHA2DS2-VASc, mean (SD)a 3.1 (1.6) 3.3 (1.5) 3.1 (1.6) 1.9 (1.6)
Diabetes, n (%) 1648 (25.3) 1210 (26.5) 315 (25.4) 123 (17.1)
Hypertension, n (%) 3261 (50.0) 2302 (50.5) 696 (56.2) 263 (36.5)
Vascular disease, n (%)b 1657 (25.4) 1219 (26.7) 323 (26.1) 115 (16.0)
Congestive heart failure, n (%) 976 (15.0) 771 (16.9) 161 (13.0) 44 (6.1)
Transient ischemic attack (TIA), n (%) 271 (4.2) 188 (4.1) 73 (5.9) 10 (1.4)
Home address in assisted living building, n (%) 765 (11.7) 599 (13.1) 93 (7.5) 73 (10.1)
Number of INR measurements in 2017, mean (SD) 15.4 (11.0) 15.9 (10.9)
Standard TTR definable in 2017, n (%) 3524 (54.1) 3307 (72.5)
aAnticoagulation medication should be used for patients having the score of 2 or more
bVascular disease includes the following ICD-10 codes: I20-I25, I70.9
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average gross wage per hour instead of 20%, or at 50%
instead of 35%. Depending on the number of measure-
ments and the value of lost leisure time, the share of
indirect costs varies between 21.9 and 29.0% compared
to 26.6% in the baseline.
The second sensitivity analysis was done for the an-
nual travel costs (Table 7) using the five distances and
the four numbers of INR monitoring visits. As the dis-
tance would not have been suitable measure for all
four travel modes, for these sensitivity results every pa-
tient was determined to use private car. Reportedly,
costs increase linearly with increasing distance and the
increasing number of trips.
Finally, we estimated the cost change of the shift of
all eligible patients from warfarin to DOAC (Table 8).
In the tested scenario, 81.4% (N = 3711) of the patients
currently using warfarin were shifted to use DOACs,
and 18.6% (N = 849) were determined to continue
using warfarin due to the formerly described restric-
tions to DOACs or due to a falsely low number of an-
nual INR measurements. With retail prices excluding
VAT, the total cost of anticoagulation management
Fig. 2 Geographical differences in the usage of warfarin, and the travel distances to INR sampling points along the road network. The map on
the left is based on Empirical Bayesian Kriging (EBK) interpolation for patient locations in a 2 km × 2 km grid. The figure has been generated with
ArcGIS 10.5 software (Esri, Redlands, CA, USA), and it is freely available to use
Table 4 Baseline: Annual costs of warfarin therapy (2018 prices)
Annual Cost (EUR) Share (%) Per Patient (EUR)
Total cost of warfarin therapy: 3,789,930 100.0
Direct costs 2,781,820 73.4 610 (N = 4560)
INR measurements and monitoring 2,570,450 67.8 564 (N = 4560)
Warfarin medication 211,370 5.6 46 (N = 4560)
Indirect costs 1,008,110 26.6
Time costs of INR measurements and monitoring 193,020 5.1 42 (N = 4560)
Travel costs 715,990 18.9 181 (N = 3961)
Travel time costs 99,100 2.6 25 (N = 3961)
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Table 5 Baseline: Travel costs in warfarin therapy (2018 prices)
Costs (EUR) Private Car (N = 2132) Taxi (N = 925) Bus (N = 358) Walking (N = 546) All Travel Modes (N = 3961)
Total annual cost 285,790 464,850 53,200 11,250 815,090
Direct travel costs 235,260 444,360 36,370 715,990
Time costs 50,530 20,490 16,830 11,250 99,100
Average annual cost per patient 134 503 149 21 206
Average monthly cost per patient 11 42 13 2 17
Average cost of one journey 9 29 11 2 14
Patient age Average annual cost (the cost of one journey in parentheses)
Age < 63 years 190 (15) 191 (16) 52 (4) 170 (13)
Age≥ 63 years 129 (9) 512 (29) 141 (10) 18 (1) 208 (14)
Travel distance Average annual cost (the cost of one journey in parentheses)
Distance < 5 km 42 (3) 310 (18) 133 (10) 21 (2) 117 (8)
Distance 5–10 km 121 (8) 701 (38) 167 (12) 220 (15)
Distance 10–20 km 229 (16) 870 (59) 362 (25)
Distance ≥20 km 395 (29) 2006 (102) 662 (45)
INR measurements Average annual cost (the cost of one journey in parentheses)
INR M. per year ≤6 33 (11) 124 (36) 32 (11) 4 (1) 44 (14)
INR M. per year 7–12 91 (9) 277 (28) 105 (11) 15 (2) 117 (12)
INR M. per year 13–20 152 (10) 454 (28) 172 (11) 23 (1) 214 (13)
INR M. per year > 20 246 (8) 912 (30) 324 (11) 46 (2) 427 (14)
Table 6 Sensitivity analysis for the costs of warfarin therapy (2018 prices)
Annual cost EUR (share %
from the total cost)
Number of annual INR
measurements:
Number of annual INR
measurements:
Number of annual INR
measurements:
Number of annual INR
measurements:
5 10 15 20
The value of leisure time
(%/gross wage per hour):
The value of leisure time
(%/gross wage per hour):
The value of leisure time
(%/gross wage per hour):
The value of leisure time
(%/gross wage per hour):
20 35 50 20 35 50 20 35 50 20 35 50
Total cost of warfarin therapy: 1,291,
770
(100)
1,324,
700
(100)
1,357,
630
(100)
2,372,
160
(100)
2,438,
030
(100)
2,503,
890
(100)
3,452,
560
(100)
3,551,
360
(100)
3,650,
150
(100)
4,532,
950
(100)
4,664,
690
(100)
4,796,
410
(100)
Direct costs 1,009,
370
(78.1)
1,009,
370
(76.2)
1,009,
370
(74.3)
1,807,
370
(76.2)
1,807,
370
(74.1)
1,807,
370
(72.2)
2,605,
370
(75.5)
2,605,
370
(73.4)
2,605,
370
(71.4)
3,403,
370
(75.1)
3,403,
370
(73.0)
3,403,
370
(71.0)
INR measurements and
monitoring
798,000 798,000 798,000 1,596,
000
1,596,
000
1,596,
000
2,394,
000
2,394,
000
2,394,
000
3,192,
000
3,192,
000
3,192,
000
Warfarin medication 211,370 211,370 211,370 211,370 211,370 211,370 211,370 211,370 211,370 211,370 211,370 211,370
Indirect costs 282,400
(21.9)
315,330
(23.8)
348,260
(25.7)
564,790
(23.8)
630,660
(25.9)
696,520
(27.8)
847,190
(24.5)
945,990
(26.6)
1,044,
780
(28.6)
1,129,
580
(24.9)
1,261,
320
(27.0)
1,393,
040
(29.0)
Time costs of INR
measurements and
monitoring
35,640 57,040 78,440 71,270 114,080 156,880 106,910 171,120 235,320 142,550 228,160 313,770
Travel costs 224,700 224,700 224,700 449,410 449,410 449,410 674,110 674,110 674,110 898,810 898,810 898,810
Travel time costs 22,060 33,590 45,120 44,110 67,170 90,230 66,170 100,760 135,350 88,220 134,350 180,460
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would increase 2.6% when warfarin is replaced with
DOAC for as many patients as possible. In the alterna-
tive DOAC scenario, applying the drug distributor’s
pricing, the total cost decreases 13.6%.
Discussion
The hindrance to the extensive shift from warfarin to
DOACs in anticoagulation management has been the
high price of the new drugs. However, when measuring
the total societal costs of the therapy, the indirect costs
of warfarin are often ignored. Our modeled results in
the region of North Karelia show that when INR is
measured routinely in local clinics, travel and time
costs can constitute over 25% of the total societal costs
of warfarin therapy.
In our study area, the mean travel cost per INR moni-
toring visit (including time costs) varies from 2 to 29
EUR depending on the travel mode, with an average of
13.5 EUR for all travel modes. A previous multinational
study by Jowett et al. [10] conducted by questionnaire
reported mean patient costs (including travel costs, fee
paid by patients, and the time costs of travel and clinic
attendance) per visit of 12.8 EUR in Australia, 19.5 EUR
in Spain, 18.3 EUR in Sweden, and 15.6 EUR in the UK
(adjusted for inflation from 2003 to 2018). To fully com-
pare our results with these previous results, the average
time cost of INR measurement and warfarin dosage
adjustment (2.7 EUR) must be added to the travel re-
lated costs. After this adjustment, the comparable mean
patient cost per visit is 16.2 EUR in our study area. This
is well in line with the findings by Jowett et al., consider-
ing that these two studies were executed with different
methods. It is also a decent indication that modeling can
be used to achieve comparable travel cost results with
questionnaires, especially when dealing with large-scale
patient groups and areas.
The sensitivity analysis for the travel costs of INR
monitoring shows that the costs increase in line with
travel distance and the number of monitoring visits.
Respectively, the total cost of warfarin therapy is also
highly dependent on the number of annual measure-
ments. Additionally, the sensitivity analysis for the
valuation of leisure time suggests that the value of time
has a moderate effect on the share of indirect costs in
warfarin therapy.
Our investigation on the maximal societal savings
achievable with the shift from warfarin to DOACs shows
that the total costs with these two forms of therapy can
be very similar and comparable or very different, de-
pending on the price of the DOACs. Hence, if this study
is applied in different countries, the results vary between
regions. With current Finnish retail prices (excluding
VAT), the transition to DOAC therapy would increase
the societal costs by 2.6% compared to baseline, based
Table 7 Sensitivity analysis of the travel costs when everybody
travels by car (2018 prices)
Distance
(km) by
private
car
Annual travel costs (EUR) Cost
per
journey
(EUR)
Number of annual INR monitoring visits:
5 10 15 20
2 53,860 107,720 161,580 215,450 2.7
5 114,320 228,650 342,970 457,290 5.8
10 215,080 430,150 645,230 860,310 10.9
20 416,600 833,200 1,249,800 1,666,400 21.0
30 618,110 1,236,220 1,854,330 2,472,430 31.2
Table 8 Cost change in the scenario: shift from warfarin to DOAC (2018 prices)
Annual costs in EUR (share % from total costs) Drug retail prices (excl. VAT) Distributor’s drug prices
Baseline Scenario Change Baseline Scenario Change
Costs of INR monitoring: 2,974,840 (59.8) 343,500 (6.7) −88.5% 2,881,800 (62.9) 326,180 (8.2) −88.7%
INR measurements and medication (N = 4560) 2,781,820 (56.0) 2,688,780 (58.7)
Time costs of INR monitoring (N = 4560) 193,020 (3.8) 193,020 (4.2)
Patients unable to switch to DOAC (N = 296) 270,230 (5.3) 264,190 (6.7)
Patients not switching to DOAC (< 5 INR M. 2017,
N = 553)
73,270 (1.4) 61,990 (1.5)
Travel costs: 815,090 (16.4) 97,840 (1.9) −88.0% 815,090 (17.8) 97,840 (2.5) −88.0%
Direct travel costs (N = 3961) 715,990 (14.4) 715,990 (15.6)
Travel time costs (N = 3961) 99,100 (2.0) 99,100 (2.2)
Patients continuing warfarin (N = 772) 97,840 (1.9) 97,840 (2.5)
Cost of DOAC therapy: 1,181,850 (23.8) 4,661,180 (91.4) 294.4% 883,970 (19.3) 3,531,580 (89.3) 299.5%
Patients using DOAC (N = 1239) 1,181,850 (23.8) 1,181,850 (23.2) 883,970 (19.3) 883,970 (22.3)
Patients switching from warfarin to DOAC
(N = 3711)
3,479,330 (68.2) 2,647,610 (67.0)
Total cost of anticoagulation management: 4,971,780 (100) 5,102,520 (100) 2.6% 4,580,860 (100) 3,955,600 (100) −13.6%
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on the current patient group in our study area. Respect-
ively, with lower distributor’s prices, the costs would
decrease 13.6% (in total 625,000 EUR / 725,000 USD, 1
EUR = 1.1606 USD). From a societal perspective, in our
study area this means that when considering the time
and travel costs in INR monitoring, DOAC therapy is
currently cost-efficient but not cheaper than warfarin
therapy. However, presuming that drug prices will
decrease in the future as the expiration of most DOAC
patents by 2023 allows the introduction of first generics,
the savings could be considerable when preferring
DOAC therapy over warfarin.
Marcolino et al. [14] reported that in the Brazilian
context, the cost of anticoagulation management with
DOACs is lower than with warfarin. As the average
monthly price for DOACs in this study was even lower
than the distributor’s prices in our study (54 USD vs. 68
USD, adjusted for inflation and converted on October 1,
2018), both leading to savings when compared with the
total costs of warfarin therapy, these drug prices can be
used as raw estimates for the level at which societal
savings are currently achievable.
The shift from warfarin to DOACs not only has an
impact on the societal cost of anticoagulation manage-
ment, it also removes the burden of INR monitoring
and traveling. This decreases the importance of the
spatial accessibility of health services, contributing to
better geographical equality of anticoagulation man-
agement and healthcare in general. The shift would be
even more rational from a patient’s perspective, as in
Finland after the drug reimbursement by Social Insur-
ance Institution, the purchase price of DOACs for
patients is only 35% of the original retail price. How-
ever, this out-of-pocket expense was intentionally
overlooked in this study, as we wanted to investigate
the societal lucrativeness and economic viability of the
replacement of warfarin by DOACs.
Our study reviews the accessibility setting and travel
costs in a single healthcare district in Finland. These
results are most relevant in sparsely populated rural
regions (population density of 5–20 per km2 / 15–50 per
mi2, degree of urbanization lower than 75%) with a high
proportion of elderly population (median age of the
population over 45 years). In Europe, comparable regions
can be found, for example, from other parts of Finland
and Scandinavia [34]. Many US counties also meet these
characteristics [35, 36]. Within a healthcare district, the
shift from warfarin to more expensive DOACs is less
cost-efficient in urban areas where the population has
better access to healthcare, and the sample collection
points for INR monitoring are on average closer than in
our study region. As DOAC therapy is less often the
cheaper option in urban areas, in many cases the societal
costs might be lower when using warfarin.
Our modeling setting has some limitations. Firstly,
the effectiveness of both interventions was assumed to
be equivalent. Yet DOACs have been shown to offer a
better safety profile, as they possess a lower risk of
fatal and costly complications (such as ischemic
strokes or major bleeding) associated with warfarin.
The cost of those complications was beyond the scope
of this study, which means that, as indicated previously
[37, 38], the cost reduction enabled by DOACs is most
likely even greater than in our study setting. Secondly,
the time loss of a possible escort for INR monitoring
visits made by older patients was not considered,
which for its part leads to a slight underestimation of
the total societal cost of INR monitoring in warfarin
therapy. Thirdly, we left the temporal variability of
accessibility unconsidered, even though it might affect
the availability of services in some frequently visited
laboratories.
The research use EHRs is increasing, as they enable
large-scale, up-to-date studies [39]. By combining pa-
tient register data with GIS methods, health research
can be spatialized. This opens new possibilities for the
assessment of regional health differences, and it pro-
vides real-world information for healthcare planning.
Our modeling approach can be used as a baseline for
measuring time and travel costs of different healthcare
processes that require patient monitoring. The model
can also be expanded and developed further to suit
different geographical regions with alternative travel
patterns.
Conclusion
As a conclusion from our study setting, the results sug-
gest that the amount of patients’ travel and time costs
critically increase the societal cost of INR monitoring
and warfarin therapy, and these cost types should not be
overlooked. From a societal perspective, despite the
higher price of DOAC drugs, they are a cost-efficient
alternative to warfarin in anticoagulation management.
As a more comprehensive continuation in the future, it
would be important to also include the cost of AF com-
plications in the cost comparison between warfarin and
DOACs. In addition to the costs modeled in this study,
also the effectiveness of warfarin and DOACs should be
assessed using the same patient sample.
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